Natco Pharma launches Pomalidomide Capsules in Canada

01 Mar 2023 Evaluate

Natco Pharma has launched Pomalidomide Capsules in Canada, the first generic alternative to POMALYST brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients with multiple myeloma. Multiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells. It is the second most common form of blood cancer in Canada with about 8,000 Canadians living with myeloma.

Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules and available through the RevAid risk management platform. This launch reflects Natco’s continued investment in Canada to expand portfolio of high-quality generic medicines at affordable prices.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

860.00 -31.90 (-3.58%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×